DGAP-Adhoc: INJEX Pharma AG: Injex Pharma AG announces changes to it's Executive Management Board

INJEX Pharma AG / Key word(s): Change of Personnel

17.05.2013 10:55

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc Release: Injex Pharma AG announces changes to it's Executive
Management Board

Berlin, May 17, 2013 - Injex Pharma AG announces the appointment of Dr.
Thomas Klaue as member of the Executive Board with immediate effect. He
will serve as the CEO of Injex Pharma AG. Andy Rösch, the founder and CEO
to date, will retire at the end of June 2013. However, he will further
support the company in the future as a consultant and as a main
shareholder.

The Chairman of the Supervisory Board of Injex Pharma AG, Dr. Peter
Heinrich, commented: 'On behalf of the Supervisory Board, I would like to
thank Mr Andy Rösch for the impressive job he has done as a visionary
founder and CEO in the start-up phase. His accomplishments are the basis
for the growth phase we are facing now. And we are glad having been able to
attract Mr Thomas Klaue, an experienced manager with capital markets
expertise and with senior management experience in the technology and life
science industry. He is the CEO to lead the company into the next growth
stage and to the stock market.'

'After completion of the start-up phase I am looking forward to develop
this company into the next stage. We will first reinforce our equity base
and second increase our production capacity to supply our global
distributor network', concluded the newly appointed Executive with regard
to his new assignment.

The Harvard Business School graduate Thomas Klaue has more than two decades
of experience as senior executive in the technology (EADS, Infineon
Technologies) and biotech/healthcare industry, i. e. with MediGene AG.
Since 2007 he served as CFO in listed companies and was appreciated by
analysts and investors for his transparent communication with the capital
market.

Injex Pharma AG is currently preparing its listing in segment General
Standard at the Frankfurt Stock Exchange.

INJEX Pharma AG
Investor Relations
t: +49 89 24 41 18 - 223
f: +49 89 24 41 18 - 499
ir@injex.com

INJEX Pharma AG:
INJEX Pharma Aktiengesellschaft and its subsidiaries INJEX Pharma GmbH and
INJEX Vertrieb Deutschland GmbH are specialized in the development,
manufacturing and marketing in the medical technology segment and in the
cosmetics and beauty markets. The Group's core business areas are the
needle-free INJEX30 system and the product line SHIREEN in the beauty
market. The main markets of the Group are North America, China, India,
Russia and Europe.

---------------------------------------------------------------------------

Language: English
Company: INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Germany
Phone: +49 89 24 41 18 - 223
Fax: +49 89 24 41 18 - 499
E-mail: ir@injex.de
Internet: www.injex.de
ISIN: DE000A0STYL7
WKN: A0STYL
Listed: Regulierter Markt in Frankfurt (General Standard)

Notierung im Regulierten Markt vorgesehen / intended to be listed at Regulated
Market

End of Announcement DGAP News-Service

---------------------------------------------------------------------------